8 completed, 3 unknown, 1 recruiting. 5 Phase 4, 3 Phase 1, 2 Not applicable, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 4, Unknown 1 |
| Phase 1 | 3 | Unknown 2, Completed 1 |
| Not applicable | 2 | Completed 1, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow this drug Literature Review of Sulfadoxine trials Research Report on Sulfadoxine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition MFGM-RUTF (milk fat globule membrane ready-to-use therapeutic food), S-RUTF (standard ready-to-use therapeutic food), Amoxicillin - Severe Acute Malnutrition, Cognitive Impairment | Not applicable | Recruiting | Washington University School of Medicine | 1600 | 2025-09-22 | 2025-12-17 |
| Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets., Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ - Fasting | Phase 1 | Unknown | Swiss Pharma Nigeria Limited | 46 | 2024-07-01 | 2024-07-26 |
| Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique Sulfadoxine/pyrimethamine plus amodiaquine - Malaria,Falciparum, Chemoprevention | Phase 4 | Unknown | Malaria Consortium | 1000 | 2024-03-26 | 2024-03-29 |
| Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine, G-COSPE® tablets - Bioequivalence | Phase 1 | Unknown | Emzor Pharmaceutical Industries Limited | 70 | 2022-12-01 | 2022-08-11 |
| Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Proguanil Oral Tablet, Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ), Dihydroartemisinin-Piperaquine (DP) - Malaria,Falciparum | Phase 4 | Completed | Duke University | 246 | 2018-01-23 | 2024-04-23 |
| Comparison of Two Strategies for the Delivery of IPTc sulfadoxine /pyrimethamine plus amodiaquine - Malaria | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 14000 | 2006-05-01 | 2017-02-10 |
| Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS), placebo tablet similar to active drug in shape and size - Plasmodium Falciparum, Asymptomatic Parataemia | Phase 3 | Completed | Tropical Medicine Research Institute | 2005-08-01 | 2008-03-28 | |
| Anti-Malarial Drug Resistance in Cameroon Amodiaquine and Sulphadoxine/Pyrimethamine - Malaria | Phase 2 / Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 755 | 2003-08-01 | 2017-01-12 |
| Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg) - Malaria, Anemia | Phase 4 | Completed | Bernhard Nocht Institute for Tropical Medicine | 1070 | 2003-01-01 | 2010-03-30 |
| Efficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy sulfadoxine/pyrimethamine, sulfadoxine/pyrimethamine plus artesunate - Malaria | Phase 4 | Completed | Centers for Disease Control and Prevention | 1614 | 2003-01-01 | 2012-09-11 |
| Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi Monthly sulfadoxine/pyrimethamine, 2-dose sulfadoxine/pyrimethamine - Malaria, Falciparum, HIV Infections | Not applicable | Completed | Centers for Disease Control and Prevention | 700 | 2002-10-01 | 2005-08-23 |
| Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome Fansidar (pyrimethamine and sulfadoxine) - Autoimmune Disease, Lymphoproliferative Disorder | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2001-03-01 | 2008-03-04 |
Malaria (5) · Malaria, Falciparum (4) · Anemia (1) · Autoimmune Diseases (1) · Autoimmune Lymphoproliferative Syndrome (1) · Birth Weight (1) · Cachexia (1) · Cognitive Dysfunction (1) · Fasting (1) · HIV Infections (1) · Kwashiorkor (1) · Lymphadenopathy (1) · Lymphoproliferative Disorders (1) · Severe Acute Malnutrition (1) · Splenomegaly (1)
Centers for Disease Control and Prevention (2) · London School of Hygiene and Tropical Medicine (2) · Bernhard Nocht Institute for Tropical Medicine (1) · Duke University (1) · Emzor Pharmaceutical Industries Limited (1) · Malaria Consortium (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Swiss Pharma Nigeria Limited (1) · Tropical Medicine Research Institute (1) · Washington University School of Medicine (1)
Ghana (1) · Jordan (1) · Kenya (1) · Malawi (1) · Sierra Leone (1) · Sudan (1) · Tanzania (1) · The Gambia (1) · United States (1)
Badria B El Sayed, PhD,MSc,BSc (1) · Indi Trehan, MD, MPH (1) · John MacArthur, MD, MPH (1) · Kalifa Bojang, MD (1) · Kevin B Stephenson, MD (1) · Majdi Abu Awida, Doctor (1) · Mark J Manary, MD (1) · Ohene Adjei, Prof. Dr. (1) · Salim Abdulla, MD, PhD (1) · Sam Gudoi (1) · Scott J Filler, MD, DTM&H (1) · Wilfred Mbacham, ScD (1)
PMID 39324693, PMID 16826475, PMID 18067679, PMID 18828899, PMID 21304921, PMID 34585740, PMID 36215323
R01HL134211 (1)